



MARKETING

Novartis calls off 3 Beovu trials testing frequent dosing on concerns of vision threatening side effect

By Angus Liu Jun 1, 2021 11:41am

[age-related macular degeneration](#)

[drug safety](#)

[VEGF](#)

[Beovu](#)

Top 11 Pharma Trends to Watch through 2023 - Learn about the trends affecting the pharmaceutical industry moving forward.

Sponsored by IQVIA

Even as COVID-19 transitions to an endemic virus, economic factors put pressure on margins. From 340B dollars in equity issues to affordability economics and digital spend inefficiencies, IQVIA explores what's in store for the industry.

[LEARN MORE](#)

Friday, Novartis said it had [decided to nix](#) three Beovu trials early after an interim analysis of the Merlin study found increased rates of inflammation of the eyes in patients who got Beovu compared to those who received Regeneron and Bayer's rival Eylea.

The Merlin trial, as well as the Raptor and Raven studies, were testing Beovu given every four weeks. The drug currently carries an FDA label for dosing every eight to 12 weeks after three initial doses.

Novartis said it has communicated the data to health authorities and will seek an update on the drug's label. It will also amend the protocols of other ongoing Beovu trials to remove the four-week dosing during the maintenance phase.



FIERCE EVENT

Register now for super early-bird savings!

[Register](#)

📅 October 18-20, 2022

📍 Philadelphia, PA

Novartis launched the Merlin trial to see if the more frequent dosing could help age-related macular degeneration patients who still have unresolved retinal fluid despite anti-VEGF therapy. In the front, 6 mg monthly Beovu matched up to 2 mg monthly Eylea in change in visual acuity. The drug also bested Eylea on some anatomical secondary endpoints, Novartis said.

hopes for the drug as it matched Eylea in best-corrected visual acuity and showed it o retinal fluid. Now, though, the drug has almost disappeared from Novartis' public disc financial performance. And with the latest safety finding, Novartis will likely have a ha confidence in Beovu.

In the first quarter, Beovu only pulled in \$39 million in sales, a 44% decline over the p safety scare and the pandemic's constraint on the overall ophthalmology market. Tha Eylea's 15% U.S. sales boost during the same period to \$1.35 billion.

The company has yet to identify the root cause behind Beovu's safety problem.

[Pharma](#)

[Marketing](#)

[Novartis](#)

RESOURCE CENTER

Report

ASCO 2021 Highlights

The ASCO Annual Meeting gathers oncology professionals from around the world to discuss the latest in cancer research and treatment than 2,500 abstract presentations - and while each study is valuable, we want to share comments on a few topics of particular interest.

Article

Managing Clinical Trial Complexity

The three factors driving up average study duration, and how to respond. Complexity isn't going anywhere, so instead of reducing these manage them [Learn more](#).

Subscribe

I acknowledge that I may receive emails from FiercePharma and on behalf of their trusted

RELATED ARTICLES



ACC: Bayer's Kerendia cuts cardio and kidney complications in high-risk patients

Apr 4, 2022 12:47pm



Komodo and cancer charity map out dealing with the colorectal cancer

Apr 4, 2022 11:02am



Sanofi, Re FDA review eosinophil

Apr 4, 2022 11:0



Alnylam's delayed th manufact

Apr 4, 2022 10:5



MARKETING

Komodo and cancer charity map out d with the colorectal cancer

By Sharon Klahr Coey Apr 4, 2022 11:02am

[Komodo Health](#)

[colorectal cancer](#)

[awareness campaigns](#)

[Congress](#)



Anjee Davis, The president of Fight CRC, in a #StrongArmSelfie. (Komodo Health)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.